-       Report 
- October 2025
-  334 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  371 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
             -       Clinical Trials 
- July 2025
-  60 Pages 
- Global 
   From       €1073EUR$1,200USD£944GBP 
      €1342EUR$1,500USD£1,180GBP 
            -       Drug Pipelines 
- April 2025
-  450 Pages 
- Global 
   From       €3578EUR$4,000USD£3,147GBP 
      €4472EUR$5,000USD£3,934GBP 
          -       Report 
- June 2025
-  150 Pages 
- Global 
   From       €2414EUR$2,699USD£2,124GBP 
          -       Report 
- June 2025
-  150 Pages 
- Global 
   From       €2414EUR$2,699USD£2,124GBP 
            -       Report 
- September 2025
-  140 Pages 
- Global 
   From       €3687EUR$4,123USD£3,244GBP 
      €4338EUR$4,850USD£3,816GBP 
            -       Report 
- August 2025
-  160 Pages 
- United States 
   From       €1939EUR$2,168USD£1,705GBP 
      €2281EUR$2,550USD£2,006GBP 
          -       Report 
- May 2023
-  180 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2024
-  210 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Report 
- November 2023
-  30 Pages 
- Global 
   From       €1968EUR$2,200USD£1,731GBP 
      €2460EUR$2,750USD£2,164GBP 
          -       Report 
- April 2023
-  114 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
            -       Report 
- May 2024
-  128 Pages 
- Global 
   From       €4941EUR$5,524USD£4,346GBP 
      €5813EUR$6,499USD£5,113GBP 
            -       Report 
- May 2024
-  130 Pages 
- Global 
   From       €4941EUR$5,524USD£4,346GBP 
      €5813EUR$6,499USD£5,113GBP 
            -       Report 
- August 2025
-  70 Pages 
- Germany 
   From       €1939EUR$2,168USD£1,705GBP 
      €2281EUR$2,550USD£2,006GBP 
            -       Report 
- August 2025
-  70 Pages 
- China 
   From       €1939EUR$2,168USD£1,705GBP 
      €2281EUR$2,550USD£2,006GBP 
          -       Report 
- January 2024
-  95 Pages 
- United States 
        €3131EUR$3,500USD£2,754GBP 
       
      Tizanidine is a centrally-acting muscle relaxant used to treat spasticity, a condition characterized by muscle stiffness and spasms. It is a short-acting drug, meaning it is taken as needed to relieve spasticity symptoms. Tizanidine works by blocking nerve impulses that cause muscles to contract. It is available in both oral and intramuscular forms.
Tizanidine is used to treat a variety of conditions, including multiple sclerosis, spinal cord injury, cerebral palsy, and stroke. It is also used to    treat muscle spasms caused by certain medications, such as baclofen and dantrolene. It is generally well-tolerated, with few side effects.
The tizanidine market is a small but growing segment of the central nervous system drugs market. It is used to treat a variety of conditions, and is generally well-tolerated with few side effects. As such, it is becoming increasingly popular as a treatment option for spasticity.
Some companies in the tizanidine market include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less   Read more